Clinical Trial Update: Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating PXL770 for Adrenomyeloneuropathy (AMN), a form of X-linked adrenoleukodystrophy, has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenomyeloneuropathy
• X-linked Adrenoleukodystrophy

Drugs mentioned

• PXL770 (PXL770)

Snippet

Sponsor: Poxel SA | Conditions: Adrenomyeloneuropathy | Phase 2 | Status: WITHDRAWN